Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 24;129(3):521–530. doi: 10.1038/s41416-023-02325-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer Nature Limited 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PMC Copyright notice

Fig. 1 — a Survival outcome related with INSR expression according to TCGA data. According to TCGA data, patients with RCC with higher INSR expression (n = 260) have significantly longer overall survival than those with lower INSR expression (n = 260) (median OS 92.1 months vs. 63.8 months, p < 0.001). Kaplan–Meier analysis shows that patients with metastatic renal cell carcinoma (mRCC) with low insulin receptor (INSR) expression who received axitinib have significantly worse progression-free survival (PFS) (median PFS 2.4 vs. 19.3 months, p < 0.0001) (b) and overall survival (OS) (median OS 5.6 vs. 33.7 months, p = 0.001) (c) than those with high INSR expression.